Health Care Supplies

Autobio

Autobio released FY2026 Q1 earnings on April 22 Pre-Market (BJT), actual revenue CNY 992.2 M, actual EPS CNY 0.41

Autobio released FY2025 Q4 earnings on April 22 After-Market (BJT), actual revenue CNY 1.099 B (forecast CNY 1.533 B), actual EPS CNY 0.3687

Autobio released FY2025 earnings on April 22 After-Market (BJT), actual revenue CNY 4.226 B (forecast CNY 4.207 B), actual EPS CNY 1.87 (forecast CNY 1.9761)

Autobio to Release FY2025 Earnings on April 23 After-Market (BJT), Forecast Revenue CNY 4.258 B, EPS CNY 1.9917

Autobio to Release FY2026 Q1 Earnings Report on April 23 Pre-Market BJT

Autobio released FY2025 9 Months earnings on October 29 Pre-Market (BJT), actual revenue CNY 3.127 B, actual EPS CNY 1.5034

Autobio released FY2025 Q3 earnings on October 29 Pre-Market (BJT), actual revenue CNY 1.067 B (forecast CNY 1.448 B), actual EPS CNY 0.4813 (forecast CNY 0.7)

Autobio to Release FY2025 Q3 Earnings on October 30 Pre-Market (BJT), Forecast Revenue CNY 1.448 B, EPS CNY 0.7

Autobio released FY2025 Semi-Annual earnings on August 21 Pre-Market (BJT), actual revenue CNY 2.06 B, actual EPS CNY 1.02

Autobio released FY2025 Q2 earnings on August 21 Pre-Market (BJT), actual revenue CNY 1.064 B (forecast CNY 1.368 B), actual EPS CNY 0.5521 (forecast CNY 0.57)

Autobio to Release FY2025 Semi-Annual Earnings on August 22, 2025 (BJT)

Investor Asks About AnTu Bio's Q1 Other Current Assets Composition

AnTu Biological and its Subsidiary Obtain Medical Device Registration

AnTu Bio 获得医疗器械注册证

ANTU BIOTECH shareholder Z&F reduced holdings by 260,000 shares

AnTu Biotechnology and Subsidiary Obtain Medical Device Registration Certificates

Antu Biomedical's Secretary of the Board Believes in Revenue Growth

AnTu Bio subsidiary obtains medical device registration, enriching product line

AnTuBio Secretary Responds to Investors on Trade War and Tariff Policy Impact

Autobio released FY2024 Q4 earnings on April 17 After-Market BJT, actual revenue CNY 1.091 B (forecast CNY 1.319 B), actual EPS CNY 0.4183 (forecast CNY 0.6)

603658

Autobio announcement: 2026 first quarter revenue was 992 million yuan, a year-over-year decrease of 0.37%; net profit was 236 million yuan, a year-over-year decrease of 12.39%

Wallstreetcn

Autobio: First Quarter Net Profit Reaches 236 Million Yuan, Down 12.39% Year-Over-Year%

Autobio announced that its operating revenue in the first half of 2025 was 2.06 billion yuan, a year-on-year decrease of 6.65%. Net profit was 571 million yuan, a year-on-year decrease of 7.83%

Zhitong

Autobio: Net profit in the first half of 2025 is 571 million yuan, a year-on-year decrease of 7.83%

Autobio: Net profit of RMB 571 million in the first half of the year

Autobio recently obtained multiple medical device registration certificates issued by the Henan Provincial Drug Administration, including various testing reagent kits. The acquisition of these registration certificates will enrich the company's product line and enhance competitiveness, but the impact on short-term operating performance is limited, and future sales and operating income remain unpredictable

Autobio: Obtained multiple medical device registration certificates

According to the Qichacha APP, recently, Hebi Autobio Medical Laboratory Co., Ltd. was established with a registered capital of 20 million yuan. The business scope includes: wholesale of pharmaceuticals; operation of Class III medical devices; leasing of Class III medical devices; sales of disinfection equipment, etc. Qichacha's equity penetration shows that the company is wholly owned by Autobio indirectly

Autobio has established a new medical testing company in Hebi

According to the Zhitong Finance APP, Autobio announced that the company and its wholly-owned subsidiary, Autobio Instrument (Zhengzhou) Co., Ltd. (referred to as "Autobio Instrument"), recently received a medical device registration certificate issued by the Henan Provincial Drug Administration. The acquisition of the above medical device registration certificate further enriches the company's product menu, continuously meets market demand, serves as an effective supplement to the company's existing testing products, and can gradually enhance the overall competitiveness of the company's products, with a relatively small impact on the company's operating performance in the short term

Autobio and its wholly-owned subsidiary obtained medical device registration certificates

According to the Zhitong Finance APP, Autobio announced that the company recently received five medical device registration certificates issued by the Henan Provincial Drug Administration. The acquisition of these medical device registration certificates further enriches the company's product menu, continuously meets market demand, serves as an effective supplement to the company's existing testing products, and can gradually enhance the overall competitiveness of the company's products, with a relatively small impact on the company's operating performance in the short term

Autobio obtained five medical device registration certificates

According to the Zhitong Finance APP, Autobio announced that the company and its wholly-owned subsidiary Autobio Instrument (Zhengzhou) Co., Ltd. (referred to as "Autobio Instrument") recently received medical device registration certificates issued by the National Medical Products Administration and the Henan Provincial Medical Products Administration. The product names are: Cytomegalovirus IgM Antibody Test Kit (Magnetic Particle Chemiluminescence Method), Carbamazepine Test Kit (Liquid Chromatography - Tandem Mass Spectrometry), Fully Automated Chemiluminescence Immunoassay Analyzer

Autobio and its subsidiaries have obtained multiple medical device registration certificates

According to the Zhitong Finance APP, Autobio announced that its wholly-owned subsidiary Beijing Autobio Engineering Co., Ltd. recently received a medical device registration certificate issued by the Beijing Municipal Medical Products Administration, involving the following products: "Lambda (λ-LC) Light Chain Determination Kit (Immunoturbidimetric Method)", "Kappa (κ-LC) Light Chain Determination Kit (Immunoturbidimetric Method)", and "Immunoglobulin G4 (IgG4) Determination Kit (Latex Immunoturbidimetric Method)"

Autobio(603658.SH)